Contact SCGE
Your email
Message
Send
SCGE Consortium Home
About SCGE TCDC
Contact Us
License
Home
Gene Therapy Trial Browser
Clinical Trial Report
Gene Therapy Trial Report
Summary
Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients
NCTID
NCT06292650
(View at clinicaltrials.gov)
Description
This is zM-02's safety, tOlerability, and efficacy in retinitis pigmentOsa first-in-humaN study (MOON). This trial is meant to evaluate the safety and efficacy of ZM-02 in Retinitis pigmentosa (RP) patients. Unilateral intravitreal injections (IVT) will be given into the subject's Study Eye.
(Show More)
Development Status
Active
Indication
Retinitis Pigmentosa
Disease Ontology Term
DOID:10584
Compound Name
ZM-02
Compound Description
rAAV-PsCatCh2.0
Sponsor
Zhongmou Therapeutics
Funder Type
Industry
Recruitment Status
Recruiting
Enrollment Count
12
Results Posted
Not Available
Therapy Information
Target Gene/Variant
Ch2.0
Therapy Type
Gene transfer
Therapy Route
In-vivo
Mechanism of Action
Overexpression of protective allele/gene
Route of Administration
Intravitreal
Drug Product Type
Viral vector
Target Tissue/Cell
Delivery System
Viral transduction
Vector Type
AAV
Editor Type
Dose 1
Undisclosed low dose
Dose 2
Undisclosed high dose
Dose 3
Dose 4
Dose 5
Study Record Dates
Current Stage
Early phase1
Submit Date
2024-02-27
Completion Date
2028-12-25
Last Update
2024-12-13
Participation Criteria
Eligible Age
18 Years - 65 Years
Standard Ages
Adult, Older adult
Sexes Eligible for Study
ALL
Locations
No.of Trial Sites
1
Locations
China
Regulatory Information
Has US IND
False
FDA Designations
Orphan Drug Designation
Recent Updates
Two patients treated early 2024
Resources/Links
News and Press Releases
Patients' vision has improved significantly, Zhongmou Medical has released clinical data on "optogenetic gene therapy" for the treatment of RP, with a LogMAR decrease of 0.66
Zhongmou Therapeutics Receives Orphan Drug Designation from the U.S. FDA for ZM-02 Optogenetic Therapy to Treat Retinitis Pigmentosa
Preclinical Publications
Visual function restoration with a highly sensitive and fast Channelrhodopsin in blind mice